Ace Therapeutics Launches Preclinical Hematology CRO Services

Ace Therapeutics, a specialized contract research organization (CRO) focused on translational blood disorder research, has announced its comprehensive suite of integrated preclinical hematology CRO services. These services are designed to accelerate the discovery and regulatory advancement of novel therapeutics for a broad spectrum of hematologic diseases, including inherited anemias, autoimmune blood conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders. Traditional preclinical research often faces limitations in model translatability and end-to-end study execution, creating bottlenecks for biotech and pharmaceutical developers. Ace Therapeutics addresses these pain points through its vertically integrated services that unify in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics.

The company offers a robust collection of in vivo hematologic disease models built across multiple preclinical species, including mice, rats, dogs, and non-human primates. The model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Additionally, researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines. Beyond in vivo models, the CRO provides cutting-edge in vitro modeling platforms, including biomimetic 3D hematopoietic culture systems and patient-specific iPSC-derived disease lines.

These preclinical hematology CRO services extend across the full drug development lifecycle, from target identification and CRISPR-based validation to specialized PK/PD profiling and safety toxicology assessments. Ace Therapeutics supports all therapeutic modalities, from small-molecule iron chelators and JAK inhibitors to monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies. All research workflows adhere to standardized operating procedures with rigorous quality control to guarantee reproducible, regulatory-ready data. Clients can also collaborate on customized research programs, including custom CRISPR-edited animal lines and humanized hematopoietic models for rare hematological conditions.